Published Date: 12-May-22
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Diabetic Retinopathy Market size is expected to reach $7.7 billion by 2027, rising at a market growth of 11.3% CAGR during the forecast period.
The Proliferative segment has acquired maximum revenue share in the Global Diabetic Retinopathy Market by Type in 2020, thereby, achieving a market value of $5.0 billion by 2027. The increasing growth of this segment is attributed to the rising incidence of the medical condition across the world. Manufacturers may see this as a significant opportunity to capitalize on and extend their market share. In addition, another major factor that is propelling the growth of the segment is attributed to rapidly evolving lifestyle of consumers. With the increase in the number of people that are adopting sedentary lifestyle, incidence of proliferative diabetic retinopathy is also rising.
The Laser Surgeries market is showcasing a CAGR of 15.5% during (2021 - 2027). The increasing growth of the segment is attributed to the fact that it has a high level of acceptance and familiarity because this treatment method has been on the market for a very long time. As a result, laser operations are a lucrative investment option. Moreover, due to the longer prevalence of the surgery across the market, patients consider this surgery as a more effective treatment method for the diabetic retinopathy. Further, the laser surgery treatment also comprises the latest and advanced therapeutics technology, due to which, the efficiency of this method is higher in terms of precision and time. Hence, the growth of this segment is anticipated to expedite over the forecast period.
North America is the fastest growing region in the Global Diabetic Retinopathy Market by Region in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $2.9 billion by 2027. The Europe market is estimated to grow at a CAGR of 10.9% during (2021 - 2027). Additionally, The Asia Pacific market would showcase a CAGR of 11.9% during (2021 - 2027).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
By Treatment Type
Unique Offerings from KBV Research